Once Nightly Treatment for Narcolepsy and Other Sleep Disorders with Dr. Jordan Dubow Avadel Pharmaceuticals TRANSCRIPT
Download PDFJul 13, 2020
Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy. While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations. Avadel's once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing.
@AvadelPharma #narcolepsy #SleepDisorder #EDS #cataplexy
